Drug Profile
VDC 2008
Alternative Names: VDC2008Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bostwick Laboratories
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Intratumoural, Injection)
- 03 Nov 2014 Bostwick Laboratories terminates phase I/II trial in Prostate cancer in USA (NCT00753220)
- 15 Oct 2009 Sangretech's dendritic cell technology licensed to Bostwick Laboratories in certain territories